Adaptimmune sells TECELRA, lete-cel, afami-cel, uza-cel to US WorldMeds for $55M cash plus up to $30M milestones

Adaptimmune Therapeutics PLC

Purchase price $55M cash at close; up to $30M in future regulatory/commercial milestone payments.
US WorldMeds to offer employment to ~50% of workforce; Adaptimmune to reduce remaining staff by ~62%.
Pre-tax restructuring costs of ~$7-8M in Q3 2025; CMO, CCO, CSO departing in August.
Adaptimmune retains preclinical PRAME, CD70, allogeneic assets; restructures to support transition.
Closing expected before August 4, 2025; financed by Oaktree and Athyrium debt.

item 1.01item 2.05item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.